A 6-year antifungal stewardship programme in a teaching hospital

Infection

Volumn 41, Issue 3, 2013, Pages 621-628

  Mondain, V ^a   Lieutier, F ^a   Hasseine, L ^a   Gari Toussaint, M ^a   Poiree, M ^a   Lions, C ^b,c,d   Pulcini, C ^a,b,e  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b AIX MARSEILLE UNIV   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^e UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Aspergillosis; Candidaemia; DDD; Haematology; Quality of care

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIGEN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN ANTIGEN; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; ANTIGEN DETECTION; ARTICLE; BIOPSY; BLOOD CULTURE; CANDIDA; CANDIDEMIA; CATHETER REMOVAL; CENTRAL VENOUS CATHETERIZATION; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG CHOICE; DRUG INDICATION; DRUG MONITORING; DRUG SENSITIVITY; DRUG UTILIZATION; ECHOCARDIOGRAPHY; ELECTRONIC MEDICAL RECORD; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; FUNGUS CULTURE; FUNGUS ISOLATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INFECTION SENSITIVITY; INVASIVE ASPERGILLOSIS; LUNG LAVAGE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRESCRIPTION; PROPHYLAXIS; PROSPECTIVE STUDY; SALVAGE THERAPY; SEPTIC SHOCK; STAFF TRAINING; TEACHING HOSPITAL; TEAMWORK; TREND STUDY;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FRANCE; HEALTH CARE COSTS; HOSPITALS, TEACHING; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; PROSPECTIVE STUDIES;

EID: 84878822180     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0431-1     Document Type: Article

References (26)

1. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Référentiel national de bon usage hors GHS des antifongiques. 2008.
2. Aliyu SH, Enoch DA, Abubakar II, Ali R, Carmichael AJ, Farrington M, Lever AM. Candidaemia in a large teaching hospital: a clinical audit. QJM. 2006;99:655-63. doi: 10.1093/qjmed/hcl087.
3. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107-15. doi: 10.1097/QCO. 0b013e32834e0680.
4. Apisarnthanarak A, Yatrasert A, Mundy LM. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol. 2010;31:722-7. doi: 10.1086/653616.
5. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14. doi: 10.1086/323335.
6. Berthe A, Duclos A, Ray-coquard I, Colin C, Bleyzac N. Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology. Med Mal Infect. 2011;41:25-32. doi: 10.1016/j.medmal.2010.09. 012.
7. Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother. 2004;53:853-9.
8. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21. doi: 10.1086/588660.
9. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-77. doi: 10.1086/510393.
10. Denning DW, Kibbler CC, Barnes RA. British Society for Medical mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis. 2003;3:230-40.
11. des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corm S, Lemaitre L, Poulain D, Yakoub-Agha I, Alfandari S, Sendid B. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther. 2011;36:152-60. doi: 10.1111/j.1365-2710.2010.01166.x.
12. Dumartin C, L'Hériteau F, Péfau M, Bertrand X, Jarno P, Boussat S, Angora P, Lacavé L, Saby K, Savey A, Nguyen F, Carbonne A, Rogues AM. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother. 2010;65:2028-36. doi: 10.1093/jac/dkq228.
13. López-Medrano F, San Juan R, Lizasoain M, Catalán M, Ferrari JM, Chaves F, Lumbreras C, Montejo JC, Herreros de Tejada A, Aguado JM. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56-61. doi: 10.1111/j.1469-0691.2012.03891.x.
14. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update. Bone Marrow Transplant. 2011;46:709-18. doi: 10.1038/bmt.2010.175.
15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1-45. doi: 10.1086/599376.
16. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
17. Patel M, Kunz DF, Trivedi VM, Jones MG, Moser SA, Baddley JW. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis. 2005;52:29-34. doi: 10.1016/j. diagmicrobio.2004.12.010.
18. Pavese P, Ouachi Z, Vittoz JP, Lebeau B, Foroni L, Allenet B, Stahl JP, François P. Adequacy of new systemic antifungal agents prescriptions in a teaching hospital. Med Mal Infect. 2007;37:S223-8. doi: 10.1016/j.medmal.2007. 05.009.
19. Raymond S, Henon T, Grenouillet F, Legrand F, Woronoff-Lemsi MC, Hoen B, Limat S, Leroy J. Clinical audit on the use of expensive systemic antifungals in the Besançon University Hospital. Med Mal Infect. 2009;39:125-32. doi: 10.1016/j.medmal.2008.09.028.
20. Schelenz S, Barnes RA, Kibbler CC, Jones BL, Denning DW. Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect. 2009;58:145-53. doi: 10.1016/j.jinf.2008.12.006.
21. SFAR, SPILF, SRLF. Conférence de consensus commune. Prise en charge des candidoses et aspergilloses invasives de l'adulte. 2004.
22. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146-51. doi: 10.1093/jac/dkr244.
23. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33:338-45. doi: 10.1086/664909.
24. Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol. 2008;29:370-3. doi: 10.1086/587633.
25. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60. doi: 10.1086/525258.
26. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect. 2012;18:E389-95. doi: 10.1111/j.1469-0691.2012.03973.x.